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Abstract
Lengthy co-evolution of Homo sapiens and Mycobacterium tuberculosis, the main causative agent of tuberculosis, resulted in
a dramatically successful pathogen species that presents considerable challenge for modern medicine. The continuous and
ever increasing appearance of multi-drug resistant mycobacteria necessitates the identification of novel drug targets and
drugs with new mechanisms of action. However, further insights are needed to establish automated protocols for target
selection based on the available complete genome sequences. In the present study, we perform complete proteome level
comparisons between M. tuberculosis, mycobacteria, other prokaryotes and available eukaryotes based on protein domains,
local sequence similarities and protein disorder. We show that the enrichment of certain domains in the genome can
indicate an important function specific to M. tuberculosis. We identified two families, termed pkn and PE/PPE that stand out
in this respect. The common property of these two protein families is a complex domain organization that combines
species-specific regions, commonly occurring domains and disordered segments. Besides highlighting promising novel
drug target candidates in M. tuberculosis, the presented analysis can also be viewed as a general protocol to identify
proteins involved in species-specific functions in a given organism. We conclude that target selection protocols should be
extended to include proteins with complex domain architectures instead of focusing on sequentially unique and essential
proteins only.
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Introduction
Tuberculosis (TB) remains a major world-wide health hazard,
causing to roughly 2 million deaths per year. Approximately, one
third of the world’s population is currently infected with
Mycobacterium tuberculosis (MTB), the causative agent of TB [1,2].
MTB is an intracellular parasite, an organism notoriously hard to
fight. One of the major reasons for its persistence is the intricate
network of host-pathogen interactions which is exploited by the
bacterium and which creates a fine-tuned niche for its survival in
macrophages [3]. This has been developed during lengthy periods
of ‘‘co-habitation’’ and, consequently, co-evolution. The MTB
genome has been molded to accommodate the circumstances of
life within macrophages. In fact, the bacterium has been so
successful in this process that it is notably hard to cultivate outside
its physiological host. During the co-evolution process with
humans (cf. archeological data presenting experimental evidence
for the co-habitation of MTB and humans back to 9000 years [4]),
the genome changes within the bacterium have been facilitated by
its error-prone DNA polymerases [5]. As a result, the present
MTB organism is very close to being an obligatory intracellular
parasite.
Mycobacteria are intrinsically resistant to most commonly used
antibiotics and chemotherapeutic agents. Due to its specific
structure and composition, the mycobacterial cell wall is an
effective permeability barrier, generally considered to be a major
factor in promoting the natural resistance of mycobacteria. Only a
few drugs are active against mycobacterial pathogens, and current
treatment strategies for TB consists of 3 or 4 drugs used in
combination. However, the increasing emergence of multi-drug
resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) necessitates the development of novel
drugs [6]. Furthermore, novel drugs compatible with antiretroviral
therapy are needed to treat co-infected AIDS patients [7] and new
drugs are also required that can specifically be employed for
children. Clearly, there is an urgent need for drug development
projects that actually possess novel targets and novel mechanisms
of action [8].
A significant step towards understanding the biology of MTB
was provided by full genome sequencing of various strains of this
microorganism, including the best characterized laboratory strain,
H37Rv, that contains 3,984 genes [9]. The complete genome
sequences of several other mycobacteria have also become
available, showing various levels of divergence [10,11]. While
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genome of M. leprae is reduced to only 40% of that of MTB [12].
These genomes can also be compared to those of many other
pathogenic and non-pathogenic bacteria, as the number of fully
sequenced bacterial genomes is over 600 and is rapidly increasing.
The genomes of several eukaryotic organisms have also been
sequenced and are now largely annotated, including the human
genome. Additionally, the Human Microbiome Project (HMP) has
published the sequenced genomes of 178 microbes that exist
within or on the surface of the human body [13,14]. The plethora
of genomic sequences offers a novel platform for comparative
analyses and large-scale studies. This new source of data can help
to identify proteins in the MTB proteome that perform essential
functions ensuring the survival and virulence of the bacterium.
These proteins present potential targets for drug design.
Target selection is the crucial starting point of any drug
development process. Traditionally, this procedure relied on
established knowledge of individual proteins and their functions.
The availability of complete genome sequences opened a new era
and lead to the development of various bioinformatics methods
which can prioritize targets in an automated cost-effective way.
These approaches can take various criteria into account with the
aim to minimize the interactions with the host environment yet
specifically attack the pathogen’s growth and survival. Several such
studies focused on metabolic enzymes. In their work, Anishetty
and co-workers collected enzymes from the biochemical pathways
of MTB using the KEGG metabolic pathway database [15]. As a
result, 186 proteins were suggested as potential drug targets based
on the lack of similarity to proteins from the host H. sapiens. Hasan
and co-workers proposed a ranking system by targeting metabolic
checkpoints based on the uniqueness of their role in the pathogen’s
metabolome [16]. Additionally, targets were penalized for having
high sequence similarity to proteins of the host and of the host
flora. The targetTB database was created based on similar
principles [17]. Using flux balance analysis and network analysis,
proteins critical for the survival of MTB were first identified, and
then subjected to comparative genomics analysis with the host.
Finally, a novel structural analysis of potential binding sites was
carried out to assess the validity of a protein as a target. The
selection also incorporated data about the essentiality of proteins
using the results of experiments carried out under nutrition rich
conditions. A recent analysis constructed a proteome-wide drug
target network by linking the structural proteome of MTB with
structurally characterized approved drugs [18].
In most drug target selection protocols, the existence of a
protein structure or a structural homologue is treated as an
advantage for rational drug design. Breaking with this tradition,
Anurag and Dash suggested a list of intrinsically disordered
proteins in the MTB genome as potential drug targets [19]. This is
in accordance with the recent finding that these proteins can also
serve as promising drug targets [20], exemplified by the successful
blocking of the p53-MDM2 interaction by a small molecule [21].
Fueled by this observation, a list of proteins with disordered
protein segments were compiled and filtered for essentiality,
uniqueness and involvement in protein-protein interactions. This
resulted in 13 proposed drug targets. These proteins have a
probable role in signaling, regulation and translation, instead of
metabolisms [19].
The success of the target selection procedure critically depends
on identifying distinctive features of the pathogen that are essential
for its survival. The protein repertoire encoded by the genome
provides the initial starting set from which potential targets can be
selected based on various hypotheses. However, the optimal target
selection criteria are still a matter of considerable debate [22,23].
The prime criteria of current target selection protocols are
essentiality, lack of sequence homologues at least in the host,
and the presence of functional characterization. These criteria,
however, can lead to the overlook of several important candidates.
In the case of MTB, there are several proteins that do not meet the
aforementioned criteria but should not be disregarded as potential
targets due to their eminent biological importance. For example,
the genome sequence of MTB revealed that about 10% of the
coding of the genome is devoted to two largely unrelated families
of acidic, glycine-rich proteins, the PE and PPE families [9]. These
proteins are largely sequence specific to mycobacteria and have
been implicated in host-pathogen interactions and antigenic
variations [24]. However, most of these proteins are not essential
and their function is largely uncharacterized. An additional new
class of promising targets in MTB corresponds to signaling
elements, in particular to the pkn family of Ser/Thr protein
kinases [25,26]. These MTB proteins play essential roles in both
bacterial physiology and virulence [26], but are evolutionary
related to eukaryotic protein kinases. These protein families are
cases that challenge current target selection protocols and indicate
that different approaches for target selection are needed.
In this work, we propose a novel computational strategy based
on phylogenetic profiling and comparative proteomic analysis that
can highlight proteins involved in specifies-specific functions. This
approach takes into account the complex evolutionary scenarios
that can lead to the emergence of novel species-specific functions.
Novel function can arise from de-novo protein creation but also
from more ancient proteins by the combination of divergence,
duplication and recombination events [27]. In order to gain
insights into the contribution of the various processes, we carried
out a comparative proteomic analysis. By focusing on the causative
agent of tuberculosis, we analyzed the protein domain and
disorder content of its proteome and carried out large-scale local
sequence similarity searches to identify basic evolutionary patterns
in MTB. We show that the enrichment of certain protein families
Author Summary
Mycobacterium tuberculosis (MTB), the causative agent of
TB, is a dramatically successful pathogen that poses a
considerable challenge for modern medicine. The increase
in multi-drug resistant TB necessitates the identification of
novel drug targets and drugs with new mechanisms of
action. In this work, we developed a novel computational
strategy based on comparative proteomic analysis that can
highlight proteins involved in specifies-specific functions.
Our analyses of the proteins encoded by the MTB genome
identified two protein families that stand out in this
respect. These proteins have complex architecture com-
bining various domains and disordered segments. They are
also involved in vital functions, especially in host-pathogen
interactions. Although these proteins generally do not fit
into traditional drug design paradigms, there are several
new strategies emerging that can be used to target these
proteins during drug development. Our results challenge
current target selection protocols that largely rely on the
uniqueness and the essentiality of proteins. Instead, these
findings emphasize the importance of complex evolution-
ary scenarios that can lead to the emergence of species-
specific functions from more ancient building blocks of
proteins. The experiences gained from this work have
important implications specifically for targeting MTB, and
in broader terms, to improve current target selection
protocols in drug development.
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specific to this pathogen. The implications of these findings for
target selection are also discussed.
Results/Discussion
Comparative sequence analysis of the MTB proteome
Domain composition and disorder content of MTB
proteins. Domains represent the evolutionary building blocks
of proteins. They correspond to conserved regions of proteins with
generally independent structural and functional properties.
Proteins can be highly modular and contain different domains
[28]. The occurrence of different domains can be highly
characteristic of the organism [29]. We analyzed the domain
composition of MTB in order to identify distinctive features as
compared to other organisms.
For the definition of domains the Pfam database was used (see
Methods) [30]. Scanning the MTB proteome against the Pfam
domains revealed that the 3948 MTB proteins altogether contain
5361 instances of 2099 different domains (1592 Pfam-A and 507
Pfam-B domains) with more than 87% of the 3948 MTB proteins
containing at least one instance of a domain. Figure 1 shows the
occurrence of these domain types in two kingdoms of life
(Eukaryote and Bacteria). It can be seen that more than two
thirds of the occurring domain types are ubiquitous and can be
found in both kingdoms of life and more than half of them can be
found in the human proteome as well. The majority of these
domains can also be found in archaeal proteins (data not shown).
The second largest group of domains totaling about one quarter of
all domains cannot be found in eukaryotes but are wide-spread
among bacteria in general. These data indicate that a large portion
of the genome of MTB is common to many different organisms
pointing to their shared evolutionary history. Only about 166 of
the occurring domains are specific to mycobacteria and only 5 of
the domains were found to be specific for MTB alone.
Nevertheless, existing Pfam domains only cover about 63% of all
residues (834,389 out of 1,327,431).
Pfam domains are defined based on their evolutionary
conservation and generally correspond to globular structures
[31]. Proteins can also contain disordered segments that do not
adopt a well-defined structure [32]. These regions can serve as
domain linkers and therefore contribute to complex domain
architectures [33]. Furthermore, they can also participate in
binding to other macromolecules via a process that usually
involves a disorder-to-order transition [34]. Disordered regions
generally have distinct sequence properties and can be predicted
from the amino acid sequence [35,36]. Recently, a method called
ANCHOR that can recognize specific regions that are disordered
in isolation but can undergo a disorder-to-order transition has
been also suggested [37]. The evolutionary analysis of these
sequences, however, remains challenging, due to the composition-
al bias and low complexity of these sequences [38].
We calculated the amount of protein disorder using IUPred
[39,40] and the amount of disordered binding regions using
ANCHOR [37,41] (see Methods). At the residue level, 11.8% and
5.7% of residues were predicted to belong to a disordered segment
or a disordered binding region, respectively. Although these values
were relatively small, they represented significantly higher values
compared to many other bacteria. The fraction of disordered
proteins and disordered binding regions were even comparable to
that of simpler eukaryotes [19] [Me ´sza ´ros et al. in preparation].
Pfam domains and disordered regions characterize two different
aspects of proteins (sequence conservations vs. structural state).
Nevertheless, they tend to overlap less than it is expected by
chance. Only 7.2% of the positions with corresponding Pfam
annotations were predicted as disordered, in contrast to the
expected 11% in the random case. This difference is statistically
significant. Among the positions belonging to disordered regions,
38.6% belonged to Pfam domains. Therefore, Pfam domains and
disordered segments are largely complementary to each other,
although some overlap can occur.
Altogether, 28% of the residues of MTB proteins were not
covered by either Pfam domains or by disordered and disordered
binding regions. Most of these regions are expected to be specific
to MTB. However, the coverage of known domains can also be
limited by technical difficulties. For example, current methods
used for the identification of conserved domains may fail to
recognize distant sequence similarities between proteins form
different organisms. Additionally, these methods are also limited
by the availability of similar sequences. This effect is expected to
diminish as the number of complete genomes sequences is
increasing, as these novel sequences can help to bridge over
missing evolutionary links. Indeed, a large number of Pfam-B
domains formed by completely uncharacterized proteins suggest
that there are many protein domains waiting to be discovered and
characterized.
Categorization of MTB proteins based on their specificity
and function. We also carried out a large-scale sequence
similarity search for all proteins in MTB by comparing them to the
proteomes of a wide range of other organisms. By virtue of this
analysis, the number of homologs in other bacterial or eukaryotic
proteomes was determined for each protein present in MTB. This
allows the identification of MTB specific proteins at various levels,
as well as the collection of proteins and protein segments that are
enriched in MTB.
In order to evaluate these results, proteins were grouped
according to their level of evolutionary specificity. At the first
level, proteins that were specific to MTB and the highly similar
M. bovis were compiled. Proteins that occur only at the level of
Figure 1. Occurrences of domains of M. tuberculosis in other
organisms. The distribution of the 2099 Pfam domains present in the
proteome of MTB in Eukaryotes and Bacteria. Slices of the pie chart
correspond to different levels of specificity with purple showing
domains that can be found exclusively in MTB, blue and green showing
domains found in mycobacteria or in bacteria in general, respectively
and orange showing ubiquitous domains that can be found in
organisms from MTB to eukaryotes. Numbers of domains are given
for each slice, with number in parenthesis for ubiquitous domains
showing the number of domains present in human proteins.
doi:10.1371/journal.pcbi.1002118.g001
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contained proteins that could be found in other bacteria as well.
The last and the largest group included those proteins that were
ubiquitous from mycobacteria to eukaryotes. These groups are
mutually exclusive, accordingly, each of the 3,948 MTB proteins
were classified in one and only one group based on the number of
similar sequences in other organism groups. We also analyzed how
these proteins were distributed among various functional catego-
ries. Functional categorization was obtained from the TubercuList
database [42]. Based on this database, proteins were assigned to
one of nine functional classes (see Methods).
Figure 2 shows how various proteins are distributed at the
different levels of specificity and functional categories. Considering
the distribution of proteins among different levels of specificity the
results are consistent with the evolutionary incidence of Pfam
domains present in MTB (see Figure 1). The majority of the
proteins (over 59%) are ubiquitous and even have relatives among
eukaryotic proteins. 29% of MTB proteins are unique to bacteria
but only 7% and 5% are unique to mycobacteria and to MTB
together with M. bovis, respectively.
Proteins from the nine studied functional categories defined in
the TubercuList (see Methods) exhibited strikingly different
distributions among different levels of specificity. One of the
largest functional group, corresponding to ‘‘intermediary metab-
olism and respiration’’, as well as proteins involved in ‘‘lipid
metabolism’’, ‘‘information pathways’’ or ‘‘regulation’’ essentially
lack MTB specific proteins and are overwhelmingly dominated by
proteins that have homologs in eukaryotes. This is in agreement
with the universality and ancient origin of proteins involved in
these processes. Other functions that could be expected to mostly
contain proteins unique to MTB such as ‘‘cell wall and cell
processes’’, ‘‘insertion sequences and phages’’ and even ‘‘virulence,
detoxification and adaptation’’ include proteins from all levels of
specificity. In these cases, however, the contributions from
bacterium specific proteins are much larger. This shows that a
significant part of these processes are general to all organisms and
this shared functional background is modulated in bacteria,
mycobacteria and in MTB separately to various extents. However,
this modulation is significant in MTB even compared to
mycobacteria in general. Correspondingly, these three categories
contain a large fraction of MTB specific proteins. A distinct
functional class is presented by the ‘‘PE/PPE’’ proteins. This
group stands out from other functional groups because most of the
proteins in this group are specific to mycobacteria in general. The
largest functional category, however, corresponds to the ‘‘hypo-
thetical conserved proteins’’ for which very little information is
available. As the majority of MTB specific proteins still fall into
this category, this observation cautions that we are only at the
beginning to understand the biology of MTB. However, the
number of these proteins is expected to decrease as more and more
genomes are being sequenced and functionally annotated. For
example, 22 out of the total of 1074 conserved hypothetical MTB
proteins have a highly similar homolog in the recently character-
ized M. pneumoniae proteome [43–45]. Despite these similarities, M.
pneumoniae does not contain any PE/PPE proteins. Altogether,
figure 2 shows that the various functional categories rely on
species-specific proteins to a different extent. Interestingly, even
those functional groups that are expected to be more specific to
MTB are dominated by proteins that have homologues in a wide
range of other organisms.
MTB specific proteins vs. MTB specific processes. To
explore the relationship between MTB specific proteins versus
MTB specific processes from a different angle, we selected a
mycobacterium specific process, the synthesis and processing of
mycolic acids. Takayama et al. analyzed the mycolic acid pathway
and described 42 proteins that can be linked to this process [46].
We have collected the domains occurring in these proteins to see
how unique its building blocks are to mycobacteria (Table S1
shows these proteins together with the found Pfam domains and
the occurrences of these domains in other organisms). The 42
proteins contain 78 occurrences of 37 different Pfam domains.
The analysis of the occurrences of these domains in other
Figure 2. MTB proteins categorized by their functions and their level of specificity. MTB proteins categorized by their functions and their
level of specificity. Specificity was defined based on the similarity searches in other, bacterial and eukaryotic proteomes. Proteins that do not show
significant similarity to any proteins outside the MTB or M. bovis proteomes are considered ‘‘MTB specific’’ (purple), proteins with homologs in other
mycobaceria, other bacteria are labeled accordingly (blue and green bars). Ubiquitous proteins with homologues in all kingdoms of life are shown
with orange bars. As both functional categories and specificity levels are mutually exclusive, the sum of all bars is equal to the total number of MTB
proteins. Functional categories are numbered as follows: 1 – virulence, detoxification, adaptation; 2 – lipid metabolism; 3 – information pathways;4–
cell wall and cell processes; 5 – insertion sequences and phages; 6 – PE/PPE; 7 – intermediary metabolism and respiration; 8 – regulatory proteins; 9 –
conserved hypotheticals.
doi:10.1371/journal.pcbi.1002118.g002
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them can be found in numerous bacterial and eukaryotic proteins.
Most of these domains are also present in various human proteins.
Although these proteins carry out an essential function specific to
MTB, their sequence cannot be considered specific to
mycobacteria or any other group of bacteria.
Four out of the five remaining domains are of unknown function
(Pfam-B_2395, Pfam-B_27575, Pfam-B_25573 and Pfam-
B_30948). Although these domains do not occur in eukaryotic
proteins, other parts of the MTB proteins containing them are
much less specific in their sequence. These regions contain
commonly occurring domains and show local sequence similarity
to bacterial and eukaryotic proteins. Only 1 of the 42 examined
proteins can be considered entirely specific to mycobacteria, the
largely uncharacterized FAS-II protein (UniProt ID: P64685).
This protein solely constitutes of the DUF2662 domain,
nevertheless, very little is known about its function apart from
the fact that it is involved in fatty acid biosynthesis and has acyl-
CoA thioesterase activity. These findings suggest that organism
specific processes are not necessarily brought about by organism
specific proteins. The discrepancy between the specificity of
proteins and the specificity of processes that involve them can be
resolved by considering that protein sequence and structure
conservation (which is the basis of the definition of domains) does
not necessarily result in functional conservation. Proteins with
essentially the same fold can carry out different functions as
exemplified by many enzymes. Furthermore, the combination of
domains with relatively aspecific functions can result in highly
specific processes and pathways. For example the MTB ACP
protein (Uniprot ID: P0A4W6) contains one acyl-carrier domain
(Pfam name: PP-binding) and plays a role in meromycolate
extension. The same domain can be found in bacteria and
eukaryotes as well, even in human proteins. The human
mitochondrial NDUFAB1 protein also contains this domain but
plays a different role as the carrier of the growing fatty acid chain
during biosynthesis.
Similarity based clustering of MTB proteins. Generally,
the number of sequences similar to an MTB protein sequence
across various species can show quite large variations. The various
scenarios include organism-specific proteins, nearly ubiquitous
proteins for which the number of homologs is relatively constant
from bacteria to eukaryotes, and many other cases for which
significant enrichment/depletion of certain protein families can be
seen at certain points in evolution. In order to identify some of the
basic trends, we carried out a cluster analysis of the similarity
profiles of MTB proteins (see Methods and Table S2). Our
analysis focuses on the enrichment and depletion of protein
segments in the MTB proteome across different species. In
accordance, the similarity profiles were constructed using the
number of similar sequences in the proteome of other organisms of
each MTB protein. This is in contrast with the binary profiles
commonly used in phylogenetic profiling [47–49]. The result of
the clustering is represented as a hierarchical tree shown in
Figure 3. The tree can be dissected into 6 major branches,
grouping the MTB proteins into 6 distinct clusters. The complete
lists of proteins in each cluster are given in Table S3. For each
cluster, we calculated the number of homologs at four levels:
within MTB, in mycobacteria, in other bacteria and in eukaryotes
on average. These data, shown in Figure 4, provide a clue to
decode the basic differences among the clusters.
The distribution of proteins in these clusters is not even, cluster
3 and 4 contains the majority of MTB proteins, while cluster 5 is
the smallest with only 11 members. Four of the six clusters, clusters
1–4 show a relatively even distribution in the average number of
similar sequences in MTB, mycobacterial, bacterial and eukaryotic
proteomes (see Figure 4). The main difference between these
clusters is the absolute number of homologs in each group. This is
the largest in cluster 1 and smallest in cluster 4. Cluster 4 contains
basically all mycobacterium specific proteins. However, many
other proteins that have only a small number of similar sequences
in all organisms are also part of this cluster. Interestingly, the
average number of similar sequences in bacterial proteomes is
smaller than in either MTB or mycobacteria for each cluster. This
indicates that many proteins, although they share a common
evolutionary origin with other bacterial proteins are specifically
enriched in MTB. The largest differences in the number of similar
sequences in mycobacteria compared other bacteria can be
observed in the last two clusters. Cluster 6 represents a group of
proteins that are present in MTB in a large number, but
completely missing from bacteria other than mycobacteria and are
generally not present in eukaryotes either. Members of cluster 5
have around 10 members within MTB and other mycobacteria on
average, slightly more than in bacteria in general, but the number
of similar sequences of these proteins explodes in eukaryotes with
an average count over 390.
The clusters also differ in terms of their functional categoriza-
tion (Table 1). Each cluster can be reduced basically to three
dominant functional classes (marked with bold in Table 1).
However, there is a single category that contains at least 30% of
the proteins for each group (marked with cyan). The most
dominant functional category for cluster 1 is ‘‘lipid metabolism’’,
for cluster 2 is ‘‘cell wall and cell processes’’, and ‘‘intermediary
metabolism and respiration’’ for cluster 3. Cluster 4 – which
contains most of MTB specific proteins – is dominated by
‘‘conserved hypothetical proteins’’. The remaining two groups are
homogeneous in terms of their function, cluster 5 contains only
regulatory proteins while cluster 6 corresponds to PE/PPE
proteins. At a closer look, both of these clusters correspond to a
specific family of proteins. The smaller compact cluster of
regulatory proteins coincides with the pkn family. Members of
the pkn group are distinguished from other MTB proteins in that a
large number of similar sequences occur in eukaryotic proteomes,
while having only a few or no similar sequences in bacterial
proteomes. Members of the other, PE/PPE group contain one of
the defining domains (either the PE or PPE domains, or both)
which are exclusive to mycobacteria. A few members of this family
contained other domains that, in contrast to the defining domains,
were not specific to MTB but occurred also in other bacterial or
eukaryotic proteins. Depending on this, 25% of PE/PPE proteins
belonged to other clusters.
The disorder content and the amount of disordered binding
regions were also distributed highly unevenly among the 6 clusters.
Table 2 shows the average fraction of residues predicted to be in
disordered or disordered binding regions together with the average
length for each of the 6 clusters and for the whole MTB proteome.
The two clusters corresponding to two specific proteins families –
the pkn and PE/PPE families - had a significantly higher content
of protein disorder and disordered binding regions compared to
the other clusters and in MTB proteins in general.
The two compact clusters corresponding to pkn and PE/PPE
families stand out in several respects. The background frequencies
of the domain occurrences differ in the two cases, as the homologs
of the pkn family is more common in eukaryotes, while members
of the PE/PPE family are basically mycobacterium specific.
However, both of these groups show a drastic domain enrichment
in MTB Beside their very unusual evolutionary profiles, they also
exhibit high disorder content. Both of these properties could
indicate their functional importance. Further insights can be
Complex Protein Architectures in M. tuberculosis
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these two families in more detail.
pkn protein family. Members of the pkn family belong to
the group of eukaryotic-like Ser/Thr protein kinases (STPKs)
[25,50]. Originally these proteins were thought to be unique to
eukaryotes, however, the accumulation of genomic sequences
revealed that some prokaryotes also contain members of this
group. The bacterial signaling pathways usually rely on two-
component systems, basically consisting of a sensor histidine kinase
and a response regulator. The eukaryotic-like protein kinase genes,
however, represent an independent, additional mode of bacterial
regulation. In mycobacteria, genome sequence data indicate that
the number of STPK genes is in fact either commeasurable or
even considerably higher than those representing the usual
bacterial two-component system genes [26]. In the MTB
genome, 11 STPK genes can be identified (from pknA to pknL)
(Table S4).
STPKs are typically signal transducers that act on response to
various environmental factors. The signal is usually detected via
additional domains that are tethered to the kinase domains.
Binding of regulatory factors to the sensor domains leads to a
conformational change in the kinase domain, which activates the
signaling cascade. In the pkn family, the kinase domain, that is
located in the N-terminal region of these proteins, gives similarity
to eukaryotic protein kinases. The other sequence parts are specific
for each of the pkn protein in MTB. With the exception of pknG
and pknK, all of these proteins are highly probable to be localized
to the membrane. Furthermore, members of the pkn family
exhibit a significant amount of disorder and contain a large
number of disordered binding regions. The location of domains,
disordered segments and the transmembrane regions are shown on
Figure 5.
Reflecting the functional diversity of this family, members of the
pkn family are different structurally as well. Atomic level
information is available for the pknB, pknD and pknG proteins.
pknB contains four PASTA domains which are believed to bind
peptidoglycan fragments [51,52]. In addition, the protein is also
involved in the regulation of cell shape and growth [53]. pknD
encompasses 6 NHL domains forming an extracellular sensor
domain. These domains were shown to fold into a highly
symmetric six-bladed b-propeller [54]. In the case of pknD, ligand
binding was shown to be linked to phosphate transfer. The soluble
pknG protein consists of a rubredoxin and a tetratricopeptide
(TPR) domain flanking the kinase domain [55]. The rubredoxin
Figure 3. Clusters of MTB proteins based on local protein similarities. Hierarchical tree representing the clustering of the 3,948 MTB proteins
using their similarity profiles (see Methods). The tree was cut at 12.5% of the maximal linkage distance and the resulting 6 clusters were analyzed.
doi:10.1371/journal.pcbi.1002118.g003
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responsible for regulating the activity of pknG depending on the
redox state of the environment. The function of the TPR domain
in this case is unknown, but TPR repeats are commonly involved
in variety of functions such as extensive protein-protein interaction
in the assembly of multiprotein complexes in other bacterial
kinases [56]. pknG was experimentally shown to be essential for
avoiding the degradation of MTB cell in macrophages by
disrupting the fusion of MTB with lysosomes, albeit the exact
mechanism is still unknown [57].
For the other members of this family, basically very little
structural information is available. Significant amount of disorder
was predicted in the case of pknA, pknF and pknI. The pknA
protein was reported to be involved in cell elongation, growth and
division and a wide range of biological processes including positive
regulation of DNA binding and negative regulation of lipid
biosynthesis [58]. In contrast to the disordered pknF, pknE is likely
to include an extracellular compact domain. Despite these
structural differences, both kinases were reported to be involved
in membrane transport [59]. pknE is also known to be linked to
nitric acid stress response [60], while pknF is linked to the
regulation of glucose transport and the barrier septum formation
[61]. pknH is involved in transcriptional regulation and in the
regulation of lipid biosynthesis [62]. Furthermore, it plays a role in
the response to stress and host immune response. The functions of
pknI, pknJ and pknL are largely unknown, however, pknI was
hypothesized to be involved in cell division [63] and there is some
indication to the involvement of pknL in transcription [64]. The
largest, other soluble member of the pkn family, pknK also
encompasses a large, uncharacterized structured region, C-
Figure 4. Average similarity numbers for each of the 6 clusters of MTB proteins. Average number of sequences similar to MTB proteins in 4
groups (MTB, mycobacterial, bacterial and eukaryotic proteomes) calculated separately for the 6 clusters resulting from the cluster analysis.
doi:10.1371/journal.pcbi.1002118.g004
Table 1. Functional distribution of proteins in the 6 identified clusters.
Cluster ID 1 2 3 4 5 (pkn) 6 (PE/PPE)
cell wall and cell processes 23 7.2% 45 35.7% 182 15.4% 521 23.9% 00 % 00 %
intermediary metabolism and respiration 67 20.9% 40 31.7% 464 39.3% 349 16.0% 00 % 00 %
lipid metabolism 128 39.9% 9 7.1% 74 6.3% 34 1.6% 0 0% 0 0%
information pathways 1 0.3% 1 0.8% 78 6.6% 161 7.4% 0 0% 0 0%
regulatory proteins 61 19.0% 28 22.2% 56 4.7% 39 1.8% 11 100% 00 %
virulence, detoxification, adaptation 12 3.7% 2 1.6% 57 4.8% 139 6.4% 0 0% 0 0%
PE/PPE 0 0.0% 0 0.0% 10 0.8% 32 1.5% 0 0% 125 100%
insertion seqs and phages 0 0.0% 0 0.0% 57 4.8% 52 2.4% 0 0% 0 0%
conserved hypotheticals 28 8.7% 1 0.8% 201 17.0% 844 38.6% 00 % 00 %
unknown 1 0.3% 0 0.0% 2 0.2% 13 0.6% 0 0% 0 0%
Total 321 100.0% 126 100.0% 1181 100.0% 2184 100.0% 11 100% 125 100%
Distribution of proteins according their functional categories for the 6 identified clusters. Numbers in italics indicate the dominant functions in each cluster and bold
typesetting marks the most abundant function.
doi:10.1371/journal.pcbi.1002118.t001
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precise function of this region is unknown, the protein is involved
in the regulation of transcription factor activity [65].
PE/PPE protein family. PE and PPE proteins represent the
most variable group of proteins in pathogenic mycobacteria
[66,67]. The PE/PPE protein family contains 167 members and
Table 2. Amount of disorder in the 6 identified clusters.
Cluster ID
Number
of proteins
Average
protein length
Fraction of
disordered AA
Fraction of AA in disordered
binding regions
1 321 468 6.04% 3.18%
2 126 371 5.92% 3.28%
3 1181 415 8.68% 5.16%
4 2184 260 13.60% 8.70%
5 (pkn) 11 620 24.17% 17.88%
6 (PE/PPE) 125 514 35.02% 11.69%
Total MTB 3948 336 11.76% 6.77%
Distribution of residues in disordered and disordered binding regions in the 6 identified clusters.
doi:10.1371/journal.pcbi.1002118.t002
Figure 5. pkn protein domain architectures. Domain architecture of the 11 members of the pkn protein family. Colored boxes below the black
lines represent predicted Pfam domains, with the defining kinase domain shown in green, transmembrane regions are marked with black boxes and
disordered regions are shown in red.
doi:10.1371/journal.pcbi.1002118.g005
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groups (with 35, 64 and 68 members, respectively) (Table S5).
Despite their importance, these proteins comprise a yet greatly
unexplored area as both structural and functional data concerning
them are scarce.
The domain organization of these proteins was assessed using
the Pfam domains and is shown in Figure 6. Almost all proteins
contain a domain at the N-terminal region that defines the family
(PE domains in the PE and PE-PGRS groups and PPE domains in
the PPE group). All three groups have a small number of dominant
domain configurations with which the majority of their proteins
can be described. In the case of PE proteins, this configuration
consists of a single PE domain optionally followed by a protein
segment containing no known domains (26 out of 35 proteins).
Similarly, most PE-PGRS proteins (45 out of 64) consist of a single
PE domain followed by a protein segment of varying length. PPE
group members are more homogeneously distributed between the
different domain configurations, however the majority of them
either contain a single PPE domain (followed by a segment of
varying length), much like the PE or PE-PGRS proteins or a PPE
domain followed by a PE-PPE_C domain (36 out of 68). A notable
sub-group of the PPE group consists of 8 proteins, each containing
a number of Pfam-B 705 domains, separated by repeats of the
pentapeptide 2 domain and optionally a few other additional
domains of unknown function (these proteins are also termed PPE-
MPTR). The function of both the Pfam-B 705 domain and the
pentapeptide repeats are unknown. However, as these modular
proteins represent the longest members of the PE/PPE family
ranging from 714 to 3300 residues in length, their structural and
functional characterization is definitely of importance.
Figure 6 also shows the predicted disordered regions in the
members of the PE, PE-PGRS and PPE groups. It is clear that
protein disorder is not homogeneously present in all three groups.
The majority of the disordered regions can be found in the PE-
PGRS proteins. Although most disordered parts do not include
any predicted Pfam domains, some domains significantly overlap
with these regions. For example Pfam-B 33425, 20497, 37359,
13848 and 77056 domains seem to be almost entirely disordered.
On the other hand, some domains, such as the a/b hydrolase
domain (Abhydrolase_3), the Pfam-B 3678, 32211 and 3678
domains seem to be entirely ordered and hence might lend
themselves to traditional structure determination possibly yielding
potential drug targets.
In an extensive comparative genomics study, it was shown that
PE and PPE genes evolved within the ESAT-6 gene cluster which
codes for an entire machinery to secrete potent T-cell antigens
[68]. In accordance with this, a PE protein could be identified in
MTB cell culture filtrates as a proof of secretion [69]. In vivo
essentiality screens showed that several of the PE/PPE proteins are
essential for growth in infected mice [70]. These same proteins are
coded within an ESAT-6 genomic region involved in pathogenic-
ity [68]. Several reports also point to the fact that members of the
PE and PPE families are transcribed together and function as
heteromers on the cell surface [68,71–73]. Several of these
proteins were shown to elicit a potent T- or B-cell immune
response [72,74,75]. Due to the variability of their C-terminal
region and their sequential properties prone to mutagenesis, the
PE-PGRS proteins in particular are regarded as a possible source
of variable surface antigens which provide a means to exploit and
possibly escape the host immune system during pathogenesis
Figure 6. PE/PPE protein domain architectures. Domain architecture of the members of the PE/PPE protein family (PE, PE-PGRS and PPE).
Colored boxes below the black lines represent predicted Pfam domains, red boxes above the black lines represent predicted disordered regions.
Numbers in parentheses show the number of proteins belonging to the respective class.
doi:10.1371/journal.pcbi.1002118.g006
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proteins into multigenic vaccines. The cross-protection against
MTB has already been shown after priming the immune system
with a PE antigen containing T-cell epitopes [74]. Although the
exact function of none of the PE/PPE proteins or of their
complexes has been revealed, the above findings delineate a
consistent picture which suggests that the PE/PPE proteins are
involved in a highly plastic host-pathogen interaction network.
Implications for target selection in drug design
In this work we carried out a comparative genomic study based
on the content of domains and disordered regions and the result of
large-scale sequence similarity searches. This approach is com-
pletely general and could be applied to any kind of organism with
an annotated genome. Here, we focused on MTB, the causative
agent of tuberculosis. Our analyses revealed two protein families in
the proteome of MTB that stand out in several aspects. These
proteins were also shown to have a functional importance essential
for the survival of this pathogen. Next, we will examine them as
potential targets for drug design.
The common properties of both the pkn and PE/PPE families
include unusual domain accretions specific to this organism. This
is combined with an increase in their disorder content. Both
families carry out important functions in the MTB and are
involved in the interactions with the host cell. Various members
were shown to be essential for the organism and according to a
recent analysis using guinea pig model, representatives of these
families are significantly enriched in the early and chronic stages of
infections [76]. Furthermore, many of them are either located in
the surface of the bacteria or are exported into the host cell. The
properties of these protein families underscore their biological
importance and suggest that they would be ideal candidates for
drug design. However, conventional drug design procedures
generally overlooked such proteins as targets by largely focusing
on metabolic processes. The need for novel drugs for the treatment
of MTB forces researchers to explore new directions for target
selection. The pkn and PE/PPE families, through their complex
architectures offer several options in this regard.
One of the most active areas of therapeutic research involves
developing protein kinase inhibitors. With recent advances,
protein kinases have now become the second most important
group of drug targets after G-protein-coupled receptors [77].
Currently, three protein-kinase inhibitors are already in clinical
use, and several other protein-kinase inhibitors are undergoing
human clinical trials, mostly targeting cancer [77]. However,
kinases may also be exploited in the development of novel
antibiotics against mycobacteria. Mycobacterium tuberculosis contains
11 eukaryotic-like Ser/Thr protein kinases (STPKs). All of these
proteins accommodate the common catalytic domain and the 12
conserved motifs that define the signature of eukaryotic protein
kinases. Despite these similarities, the sequence identity to the
human SPTK genes is around 30%, low enough to allow the
promising search for species-specific inhibitors [26]. Recently, a
high-resolution 3D structure of the pknG kinase in complex with a
potent antimycobacterial compound was published [55]. This
structure revealed that despite similarities in the overall fold of the
conserved kinase domain, the species-specific structural charac-
teristics of the protein still allows highly specific interaction
patterns with the promising drug-like compound. The structure of
the catalytic domain of pknB in complex with different ATP
analogues was also published [78,79] and revealed that in contrast
to the similar kinase structures from eukaryotes, an important
regulatory loop shows high degree of flexibility in the mycobac-
terial kinase preventing its localization in the crystal structure.
Dimerization of signaling kinases is a frequently observed
phenomenon, and within the architecture of the dimer interfaces,
species-specific and conserved elements are both found [80,81].
Specifically, the dimerization of the mycobacterial STPK proteins
seems to be universal and functionally relevant [82], therefore the
identified intermolecular interfaces may present a further target
surface to perturb protein function.
The additional sequence regions tethered to the common kinase
domain are specific for each of the pkn proteins. As most of these
domains are located outside of MTB cells, they could be more
accessible for potential drugs. Although there is detailed structural
information available for pknB, pknD and pknG proteins, they
offer very few clues about potential ‘‘druggable’’ sites. According
to their disorder profiles (Figure 5), pknE, pknK and to some
extent pknJ are likely to contain additional ordered domains. The
future structural characterization of these regions could offer
further drug target sites. Concluding on the question whether
mycobacterial kinases may present useful targets against MTB, we
wish to emphasize that due the fact that many critical cellular
processes in human are regulated by kinases, cross-reactivity could
have dramatic consequences [83,84]. In order to alleviate such
effects, we propose to focus on a combined approach which allows
targeting different elements of a mycobacterial kinase (eg
dimerization domain). In such an approach, targeting the MTB-
specific active site components of a kinase (eg. pknG), may be
coupled to designing potentially inhibitory small molecular
compounds that bind to MTB-specific sequence elements outside
the active site.
The PE/PPE proteins are similar to pkn proteins in the sense
that they also contain a well-conserved N-terminal domain that
defines these families and C-terminal parts that show large
variations in terms of their length, domain composition and
disorder content. Despite the obvious biological importance of
these proteins, very little structural and functional information is
available for them. In a large-scale structural genomics approach it
was found that individual members of both PE and PPE families
did not express well or expressed in insoluble or unfolded forms
[73]. To explain the failure of structure determination efforts it
was suggested that these proteins need partners to fold. Indeed, via
a genomic analysis one specific pair of PE and PPE proteins was
predicted to interact, and their structure was successfully
determined [73]. The extensive interface formed between the
PE and PPE domains, that also contain the conserved N-terminal
motifs, can also be considered from the viewpoint of drug design.
This is supported by the growing number of examples of small
molecules successfully blocking protein-protein interactions [85].
PE/PPE proteins also contain several additional ordered domains
(Figure 6), however, they lack detailed structural information. In
most cases, functional and structural information cannot be
inferred from sequence homologs, as the family itself is highly
specific to Corynebacterineae with the vast majority of PE/PPE
members being present in mycobacteria only. There are, however,
some exceptions, like the a/b hydrolase 3 domain, that is a
catalytic domain found in a very wide range of enzymes [86], or
the phosphoglycerate mutase (PGAM) domain that catalyses
reactions involving the transfer of phospho groups between the
three carbon atoms of phosphoglycerate [87].
Another common property of several members of both families
is the presence of long disordered segments. Until recently, the
feasibility of targeting proteins without a well-defined structure was
unclear for the purpose of drug development. There is now,
however, a newly sparked interest in intrinsically disordered
proteins as potential drug targets [88,89]. This originates partly
from recognizing the biological importance of disordered proteins,
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realizing the specific mode of their binding [32,90]. Disordered
proteins usually interact via a coupled folding and binding process
that involves a transition from a largely flexible state to a more
ordered state [34]. This transition is associated with a large
entropy cost that can make the overall binding quite weak while
maintaining specificity. The low binding free energy of these
interactions indicates that they would be relatively easy to block by
small molecules [20]. In one example, a promising small, drug-like
molecule was found to bind into the groove of MDM2. This
molecule inhibits the association of the ordered protein MDM2
with the disordered segment of p53 by mimicking the short alpha
helical structure of p53 adopted upon binding. In another
example, dimerization of two disordered proteins, c-Myc and
Max, was blocked by specific inhibitors [89]. Generally, the
analysis of known examples of the druggable regions of disordered
proteins indicated that these segments overlapped with the binding
regions predicted by ANCHOR [91]. Therefore, ANCHOR [41]
and other disordered binding region prediction algorithms that
will be hopefully developed in the years to come can be extremely
useful to highlight potential druggable sites directly from the
amino acid sequence, especially in combination with other
methods. According to our results, both pkn and PE/PPE protein
families contain putative druggable sites located in disordered
segments. For example, the region in the C-terminal part of pknA
(residues 419–431) can be of special interest, as here a high-
confidence disordered binding region is predicted by ANCHOR
that coincides with a high confidence predicted a helical region
predicted by PSIPRED [92] (Figure S1). This is indicative of a
special class of disordered binding regions that form an a helix
upon binding to their partner, similarly to the binding of p53 to
MDM2. The large number of disordered binding regions
predicted in the PE/PPE families indicates that there can be
many other druggable sites awaiting further characterization.
The two families highlighted in this study offer various options
for drug design. However, most members would be omitted from
traditional target selection procedures due the lack of essentiality.
In the pkn families, only pknA, pknB and pknG were shown to be
essential, while essentiality was showed for only 9 members of the
PE/PPE family. Since MTB is an obligate parasitic pathogen, it is
extremely difficult to identify genes that are required for the
optimal growth of mycobacteria under in-vivo conditions.
Depiction of the MTB proteome during infection is usually based
on a hypothesized environment that simulates the conditions
within the infected lung and defined on the basis of bacterial
response to pH, starvation and hypoxia [93–96]. Recently, the
guinea pig model was used to examine the bacterial proteome in
vivo during the early and chronic stages of the disease [76].
According to this study, various members of the PE/PPE families
and pknA were observed among the most dominant proteins in the
infected lung samples, giving further support for the importance of
these protein families. Interestingly, there were major differences
between the results of these in vitro and in vivo studies, suggesting
that none of the simulated in vitro model environments accurately
reflects the protein profile within the lung [76]. A further
limitation of studying the essentiality of individual proteins arises
from the functional overlap among members of various protein
families. Each member of the pkn group contains the kinase
domain, and they share many of their substrates despite the
differences in their sensor domains [97]. Although PE/PPE
proteins are much less well-characterized, several members of
them can also exhibit significant similarities with each other and
this phenomenon is also reflected in their domain composition.
The similarity often goes beyond the common N-terminal domain,
as many members of the PE/PPE protein family share the same
domain architecture (see Figure 6). There is a high likelihood of
functional overlap in these cases. Protein families with overlapping
functions challenge the notion of essentiality as target selection
criteria. However, by targeting the common domain of protein
families, several proteins of the pathogen can be attacked using the
same drug molecule. Relying on such multi-target drugs can be a
more efficient avenue in drug design [98]. In this respect, relatively
conserved domains that occur multiple times can be of potential
interest. Such examples include the PE and PPE domains, the
kinase domain of pkn proteins, the NHL domain that occurs twice
in the PE-PGRS groups as well as in pknD. There are several
other currently uncharacterized domains occur multiple times in
the genome of MTB (Figure 6). These proteins can provide
interesting targets for polypharmacological drugs [18].
Conclusions
The increasing number of complete genome sequences has
enabled comparative genomic analyses which can be used to
understand the distinctive properties of various pathogens and to
specifically target them based on this knowledge. In this work we
analyzed the proteins encoded by the genome of MTB from this
viewpoint. We identified two protein families, the pkn and PE/
PPE, that showed unusual species-specific enrichment of domains.
These proteins can be considered as potential targets for drug
design as they are involved in vital functions that are specific to this
pathogen. Members of both families have complex domain
architectures that combine family-specific domains with other
domains and disordered segments. The analysis presented in this
study predicts that drug design against members of these two
families may lead to promising hits; verification of this prediction
awaits further studies. It is important to emphasize that members
of these two families represent novel potentials since the
compounds that are either currently used in the clinics against
tuberculosis or are under clinical trials are directed against other
target proteins.
Although some of our findings are specific to MTB, there are
several more general implications of this study. The exclusivity of
certain proteins to a given pathogen is often one of prime criteria
used in various target selection protocols. However, our results
indicate that species-specific functions are not necessarily brought
about by species-specific proteins. In contrast, many novel
functions developed from already existing proteins. In the case
of eukaryotes, there are several notable examples, such as the
development of olfaction, reproduction, and immunity [27], where
the combination of gene duplication, divergence and recombina-
tion led to the expansion of protein families and provided jumping
points in evolution. The example of MTB shows that such
complex evolutionary scenarios play important roles in prokary-
otes as well and can be detected by species-specific enrichment of
certain protein domains or families. Protein families emerging as a
result of such processes often have complex domain architectures.
Consequently, these proteins can be approached from multiple
directions for the purpose of drug development. Besides traditional
strategies that aim to inhibit enzymatic functions, less well-
established approaches should also be considered, such as
developing compounds against protein-protein interaction sites
or disordered binding regions. Due the potential overlap within
these protein families, individual members might not comply with
essentiality. In these cases, however, a single drug can be effective
against more than one protein. These cases of functional overlap
arising from direct similarity, unlike indirect effects [99], may be
predicted based on target similarity. Taking the various factors of
Complex Protein Architectures in M. tuberculosis
PLoS Computational Biology | www.ploscompbiol.org 11 July 2011 | Volume 7 | Issue 7 | e1002118our findings into account can help to improve the success rate of
target selection protocols and drug development process.
Methods
Pfam
For the domain assignment the protein domains contained in
the Pfam database were used (http://pfam.sanger.ac.uk/) [30].
Pfam is composed of two parts, Pfam-A and Pfam-B. Pfam-A
domains are manually curated and have a distinct name (e.g.
Abhydrolase_3). On the other hand, Pfam-B domains are
automatically assigned using sequence similarity searches and
usually no additional annotation is supplied concerning them.
Pfam-B domains are not given a separate name and can be
identified by a unique numerical ID.
Sequence Dataset of Complete Proteomes (SDCP)
For the proteome-scale comparative studies, a dataset contain-
ing 1,904,578 protein sequences from 467 known complete
proteomes was assembled (20 eukaryotic and 447 bacterial
proteomes containing 392,401 and 1,512,177 proteins respective-
ly). These proteomes were taken from the UniProt ftp server
(ftp://ftp.uniprot.org/) [100].
PSI-BLAST similarity searches and similarity profiles
For the similarity searches between MTB proteins and the
proteins in the SDCP, PSI-BLAST was used [101]. First, a PSI-
BLAST profile was calculated for each of the 3,948 proteins in the
MTB proteome using the UniRef90 database, with three
iterations. Next, these profiles were used to find hits from the
proteins in SDCP, the database containing protein sequences from
467 known complete proteomes. A hit was considered significant
(the MTB and the other protein was considered similar) and was
used further on, if the e-value was below 10
24. Since the similarity
between proteins is often restricted to shorter parts of the
sequence, an explicit coverage threshold was not included in this
work. This enabled the recognition of similar domains or other
local protein regions between proteins, and was necessary for the
successful clustering of related proteins, such as the PE/PPE
families. The e-value cutoff ensured that these similarities are still
significant. Based on the alignments, all locally similar sequences
from the SDCP were collected for each protein in the MTB
proteome. Next, for each MTB protein a similarity profile was
built that contains the number of similar sequences for each of the
467 organism in the SDCP.
In general, the locally similar segments identified by PSI-
BLAST are larger than single domains. The aligned regions can
also contain disordered regions that are not excluded by the low
complexity filter. Furthermore, since the similarity searches were
centered around the MTB proteins, this analysis could also find
similarities between sequences in some cases, even if they do not
share Pfam domains.
Functional assignment
For the functional categorization of MTB proteins, data were
taken from the TubercuList server (http://genolist.pasteur.fr/
TubercuList/) [42]. According to this site, each MTB protein is
unambiguously grouped into one of the following categories:
virulence, detoxification, adaptation; lipid metabolism; informa-
tion pathways; cell wall and cell processes; insertion sequences and
phages; PE/PPE; intermediary metabolism and respiration;
regulatory proteins; conserved hypotheticals. We omitted the
unknown category that contained only 16 proteins and the
category corresponding to RNAs. Therefore, nine functional
categories were used in this study.
IUPred and ANCHOR
For the prediction of protein disorder IUPred was used (http://
iupred.enzim.hu/) [39,40]. The algorithm assigns a score between
0 and 1 for every residue in the protein. This score shows the
tendency of that residue being disordered. For the binary
categorization of residues we consider a residue disordered if it
has a score greater than 0.5, and ordered if its score is less than 0.5.
For the prediction of disordered binding regions we used
ANCHOR (http://anchor.enzim.hu/) [37,41]. Similarly to
IUPred, ANCHOR calculates the tendency of each residue being
in a disordered binding region. For binary classification, a cutoff of
0.5 was used here as well.
Cluster analysis
The input for the clustering algorithm is based on the similarity
profiles generatedfor each MTB sequence.Each profile consisted of
467 numbers that represent the number of sequences similar to the
MTB sequence in the 467 studied proteomes. In the cluster analysis
Euclidean distance was used together with Ward’s method. The
result of clustering was largely insensitive to various parameters of
the clustering, including the type of the clustering method, various
types of normalizations, parameters of PSI-BLAST. The clustering
was implemented in the R program package.
Supporting Information
Figure S1 pknA protein predictions. Structure predictions
for the pknA protein, including IUPred, ANCHOR and
PSIPRED. In the top part the kinase domain is shown in green,
the transmembrane region is shown in black and disordered
regions predicted by IUPred are shown in red. Solid black and
striped boxes in PSIPRED predictions indicate predicted a helixes
and b strands. Disordered binding regions predicted by AN-
CHOR are shown in blue boxes with color depth corresponding to
the confidence of the prediction.
(TIF)
Table S1 Proteins of mycolic acid synthesis. List of
proteins involved in the synthesis of mycolic acid. The corre-
sponding functions are shown together with the name and position
of the domains present. The last 5 columns show the number of
occurrences of the respective domains in various groups of
organisms. Bacterial specific domains are highlighted.
(XLS)
Table S2 MTB protein profiles. Profiles for each of the
3,948 MTB proteins obtained from the alignments performed on
the CPSD (see Methods).
(XLS)
Table S3 Proteins of each cluster. List of the 3,948 MTB
proteins. Proteins are defined with Uniprot IDs. For each protein,
the number of the containing cluster is given.
(XLS)
Table S4 pkn proteins. List of proteins belonging to the pkn
protein family. Proteins are defined with Uniprot IDs. For each
protein, the pknX name is given.
(XLS)
Table S5 PE/PPE family proteins. List of proteins belong-
ing to the PE/PPE protein family. Proteins are defined with
Uniprot IDs. For each protein, the pknX name is given.
(XLS)
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